(Q33338541)

English

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) (English)

1 reference

Europe PubMed Central

25 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

0 references

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

advanced malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H S Parra

1

1 reference

Europe PubMed Central

25 July 2017

L Tixi

2

1 reference

Europe PubMed Central

25 July 2017

F Latteri

3

1 reference

Europe PubMed Central

25 July 2017

S Bretti

4

1 reference

Europe PubMed Central

25 July 2017

M Alloisio

5

1 reference

Europe PubMed Central

25 July 2017

A Gravina

6

1 reference

Europe PubMed Central

25 July 2017

R Lionetto

7

1 reference

Europe PubMed Central

25 July 2017

P Bruzzi

8

1 reference

Europe PubMed Central

25 July 2017

C Dani

9

1 reference

Europe PubMed Central

25 July 2017

R Rosso

10

1 reference

Europe PubMed Central

25 July 2017

M Cosso

11

1 reference

Europe PubMed Central

25 July 2017

L Balzarini

12

1 reference

Europe PubMed Central

25 July 2017

A Santoro

13

1 reference

Europe PubMed Central

25 July 2017

A Ardizzoni

14

1 reference

Europe PubMed Central

25 July 2017

language of work or name

0 references

publication date

1 August 2001

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

92

1 reference

Europe PubMed Central

25 July 2017

3

1 reference

Europe PubMed Central

25 July 2017

650-656

1 reference

Europe PubMed Central

25 July 2017

Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Natural history and epidemiology of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Chemosensitivity and cytokine sensitivity of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Inhibition of Cell Motility by Interferon

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Simian virus 40, poliovaccines and human tumors: a review of recent developments

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Interferon therapy for neoplastic diseases in man in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Effect of interferon-alpha 2a on malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon beta

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C650%3A%3AAID-CNCR1366%3E3.0.CO%3B2-0

21 January 2018

Identifiers

10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33338541&oldid=1584459992"